NasdaqGS:KLDO

Stock Analysis Report

Executive Summary

Kaleido BioSciences, Inc. develops microbiome metabolic therapies.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Share Price & News

How has Kaleido BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.4%

KLDO

-1.2%

US Pharmaceuticals

0.07%

US Market


1 Year Return

n/a

KLDO

-6.3%

US Pharmaceuticals

8.9%

US Market

Return vs Industry: Insufficient data to determine how KLDO performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how KLDO performed against the US Market.


Shareholder returns

KLDOIndustryMarket
7 Day-0.4%-1.2%0.07%
30 Day-41.1%-1.9%-0.3%
90 Day-27.6%-2.0%-1.6%
1 Yearn/a-4.0%-6.3%11.3%8.9%
3 Yearn/a18.7%10.3%46.3%36.8%
5 Yearn/a21.6%8.8%62.1%44.3%

Price Volatility Vs. Market

How volatile is Kaleido BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kaleido BioSciences undervalued compared to its fair value and its price relative to the market?

1.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KLDO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KLDO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KLDO is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: KLDO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KLDO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KLDO is good value based on its PB Ratio (1.8x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Kaleido BioSciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-2.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KLDO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KLDO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KLDO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if KLDO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KLDO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KLDO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Kaleido BioSciences performed over the past 5 years?

-108.1%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: KLDO is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare KLDO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KLDO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: KLDO has a negative Return on Equity (-98.66%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: KLDO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: KLDO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Kaleido BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: KLDO's short term assets ($101.9M) exceeds its short term liabilities ($11.6M)

Long Term Liabilities: KLDO's short term assets (101.9M) exceeds its long term liabilities (13.7M)


Debt to Equity History and Analysis

Debt Level: KLDO's debt to equity ratio (17.6%) is considered satisfactory

Reducing Debt: Insufficient data to determine if KLDO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: KLDO has a low level of unsold assets or inventory.

Debt Coverage by Assets: KLDO's debt is covered by short term assets (assets are 6.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KLDO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KLDO has sufficient cash runway for 1.755155 years if free cash flow continues to reduce at historical rates of -62.3% each year.


Next Steps

Dividend

What is Kaleido BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate KLDO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KLDO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if KLDO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KLDO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KLDO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Kaleido BioSciences's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Alison Lawton (58yo)

1.2yrs

Tenure

US$6,644,129

Compensation

Ms. Alison Lawton has been the Chief Executive Officer and Director of Kaleido BioSciences, Inc. since August 2018 and has been its President since December 2017. Ms. Lawton initially joined the Kaleido Bi ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Alison's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Alison's compensation with company performance.


Management Age and Tenure

0.8yrs

Average Tenure

54yo

Average Age

Experienced Management: KLDO's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

58yo

Average Age

Experienced Board: KLDO's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$13,999,99506 Mar 19
Flagship Pioneering
EntityCompany
Shares933,333
Max PriceUS$15.00
BuyUS$999,49305 Mar 19
Michael Bonney
EntityIndividual
Role
Chairman of the Board
Executive Chair
Shares71,520
Max PriceUS$14.65

Ownership Breakdown


Management Team

  • Mike Bonney (61yo)

    Executive Chair

    • Tenure: 0yrs
    • Compensation: US$9.92m
  • Alison Lawton (58yo)

    CEO, President & Director

    • Tenure: 1.2yrs
    • Compensation: US$6.64m
  • Geoff von Maltzahn (38yo)

    Co-Founder & Director

    • Tenure: 0yrs
  • Josh Brumm (41yo)

    • Tenure: 0yrs
    • Compensation: US$2.95m
  • Wendy Arnold

    Senior Vice President of Human Resources

    • Tenure: 1.8yrs
  • Johan Hylckama Vlieg

    Chief Scientific Officer

    • Tenure: 0.3yrs
  • Katharine Knobil (54yo)

    Chief Medical Officer and Head of Research & Development

    • Tenure: 0.8yrs
    • Compensation: US$4.14m
  • John Davies (58yo)

    Chief Technology Officer

    • Tenure: 2yrs
  • Jerald Korn

    General Counsel & Corporate Secretary

    • Tenure: 0.3yrs
  • Richard Scalzo (33yo)

    Corporate Controller & Principal Accounting Officer

    • Tenure: 0.08yrs

Board Members

  • John Sculley (79yo)

    Director

    • Tenure: 0.8yrs
  • Mike Bonney (61yo)

    Executive Chair

    • Tenure: 0yrs
    • Compensation: US$9.92m
  • Theo Melas-Kyriazi (60yo)

    Director

    • Tenure: 0.3yrs
  • Laurie Glimcher (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs
  • Alison Lawton (58yo)

    CEO, President & Director

    • Tenure: 1.2yrs
    • Compensation: US$6.64m
  • Bonnie Bassler (57yo)

    Director

    • Tenure: 0.8yrs
  • Grady Burnett (45yo)

    Director

    • Tenure: 1.1yrs
  • Anthony Quinn (57yo)

    Director

    • Tenure: 3.7yrs
  • Geoff von Maltzahn (38yo)

    Co-Founder & Director

    • Tenure: 0yrs
  • Fergus Shanahan

    Chairman of Scientific Advisory Board

    • Tenure: 0.08yrs

Company Information

Kaleido BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kaleido BioSciences, Inc.
  • Ticker: KLDO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$156.400m
  • Shares outstanding: 29.79m
  • Website: https://www.kaleido.com

Number of Employees


Location

  • Kaleido BioSciences, Inc.
  • 65 Hayden Avenue
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KLDONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2019

Biography

Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infectio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:46
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.